Status:
COMPLETED
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Lead Sponsor:
Federal University of Minas Gerais
Conditions:
Late Onset Alzheimer Disease
Eligibility:
All Genders
Brief Summary
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits. Donepezil is a ChE...
Detailed Description
Patients taking donepezil were seen four times (from June 2009 to March 2013) and were submitted to the MMSE test, the Consortium to Establish a Registry for Alzheimer'sDisease battery (CERAD), and th...
Eligibility Criteria
Inclusion
- Patients fulfilling the National Institute on Aging and the Alzheimer's Association diagnostic criteria of probable AD dementia or the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences) diagnostic criteria of AD with cerebrovascular disease (AD + CVD)
- Patients presenting mild or moderate dementia according to the Clinical Dementia Rating (CDR), i.e., CDR 1 or 2, respectively
Exclusion
- Patients treated with ChEI or memantine before study entry
- Patients diagnosed with frontotemporal dementia, dementia with Lewy bodies or vascular dementia,
- Patients classified as CDR 3 or with Mild Cognitive Impairment
- Illiterate patients
- Disagreement between the first investigator and the treating physician regarding the diagnosis
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT03349320
Start Date
June 1 2009
End Date
March 1 2013
Last Update
December 18 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.